Truist Financial Has Lowered Expectations for Pediatrix Medical Group (NYSE:MD) Stock Price

Pediatrix Medical Group (NYSE:MD) had its price target dropped by research analysts at Truist Financial from $16.00 to $15.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a “hold” rating on the stock. Truist Financial’s target price indicates a potential upside of 19.43% from the stock’s current price.

A number of other research analysts also recently commented on the stock. Macquarie began coverage on shares of Pediatrix Medical Group in a research note on Monday, December 16th. They set an “outperform” rating and a $18.00 price objective on the stock. Mizuho lifted their price target on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 19th. Jefferies Financial Group upped their price objective on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. UBS Group increased their target price on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a report on Monday, November 4th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Pediatrix Medical Group has an average rating of “Hold” and a consensus price target of $16.25.

Pediatrix Medical Group Stock Performance

Pediatrix Medical Group stock opened at $12.56 on Monday. The firm has a market capitalization of $1.08 billion, a PE ratio of -4.10, a price-to-earnings-growth ratio of 2.00 and a beta of 1.58. Pediatrix Medical Group has a one year low of $6.62 and a one year high of $16.41. The stock’s 50 day moving average price is $14.34 and its 200 day moving average price is $11.52. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The firm had revenue of $511.20 million during the quarter, compared to analyst estimates of $498.87 million. During the same quarter last year, the firm earned $0.29 EPS. Pediatrix Medical Group’s quarterly revenue was up .9% on a year-over-year basis. As a group, sell-side analysts expect that Pediatrix Medical Group will post 1.26 EPS for the current fiscal year.

Insider Activity at Pediatrix Medical Group

In other Pediatrix Medical Group news, Director Mark S. Ordan sold 27,600 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total transaction of $423,660.00. Following the transaction, the director now owns 138,683 shares of the company’s stock, valued at approximately $2,128,784.05. This trade represents a 16.60 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Mary Ann E. Moore sold 8,108 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $16.00, for a total transaction of $129,728.00. Following the completion of the sale, the executive vice president now directly owns 135,810 shares of the company’s stock, valued at approximately $2,172,960. This represents a 5.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Pediatrix Medical Group

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ballentine Partners LLC acquired a new position in shares of Pediatrix Medical Group during the 2nd quarter valued at $132,000. Texas Permanent School Fund Corp boosted its stake in Pediatrix Medical Group by 29.6% during the second quarter. Texas Permanent School Fund Corp now owns 93,367 shares of the company’s stock valued at $705,000 after buying an additional 21,351 shares in the last quarter. ClariVest Asset Management LLC acquired a new position in Pediatrix Medical Group during the second quarter worth about $1,721,000. American Century Companies Inc. raised its position in Pediatrix Medical Group by 13.7% in the second quarter. American Century Companies Inc. now owns 124,395 shares of the company’s stock worth $939,000 after acquiring an additional 15,023 shares in the last quarter. Finally, WINTON GROUP Ltd lifted its holdings in Pediatrix Medical Group by 33.9% in the 2nd quarter. WINTON GROUP Ltd now owns 130,491 shares of the company’s stock valued at $985,000 after acquiring an additional 33,057 shares during the last quarter. Institutional investors own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.